- Home
- IMNM vs RVT Comparison
IMNM vs RVT Comparison
Compare IMNM & RVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | RVT |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMNM | RVT |
|---|---|---|
| Price | $23.15 | $18.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.80 | N/A |
| AVG Volume (30 Days) | ★ 754.2K | 152.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.32% |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 2.95 |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,127.34 | N/A |
| P/E Ratio | ★ N/A | $6.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.74 | $14.41 |
| 52 Week High | $27.65 | $18.81 |
Technical Indicators
Market Signals| Indicator | IMNM | RVT |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 67.39 |
| Support Level | $19.23 | $15.85 |
| Resistance Level | $25.10 | N/A |
| Average True Range (ATR) | 1.10 | 0.29 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 40.14 | 98.78 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.